Scholars Central

Conference abstractPublished 13 Jun 2016

Serum biomarkers and ovarian cancer risk: Utility for early detection and prevention

Authors: Dayan Goodenowe

Phenomenome Discoveries Inc., Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The management of ovarian cancer (OC) is difficult due to its rapid progression and the difficulty of detecting it early. Being able to detect OC early or being able to accurately identify high risk subjects for increased monitoring or for preventative surgery is critical to being able to reduce OC mortality rates. Using a non-targeted comprehensive metabolomics discovery platform, several candidate biomarkers were identified. Based upon these results, the major contributor to OC risk was hypothesized to be an overactive fatty acid desaturation and elongation system (a key process involved in cell proliferation). Low anti-inflammatory fatty acid, GTA-446 levels were also observed to contribute to OC risk. We have subsequently developed a simple metabotype test that can be performed on a single drop of blood and have successfully completed two large independent validations âÂ?Â? one from Japan (99 controls and 112 OC patients) and one from North America (1041 controls and 325 OC patients). The relative risk of OC in persons having the metabotype versus not having the metabotype was 80 in both studies with over 90% of OC subjects exhibiting the abberent metabotype. These biomarkers are based upon our unique prodrome detection technology, which identifies persons with specific metabolic abnormalities that precede the formation of specific cancers. This technology differs from traditional pathology-based cancer detection technologies in that persons who do not have these metabolic abnormalities are protected from getting the specific cancer identified by the test whereas persons exhibiting the metabolic abnormality have an elevated risk of the cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Dayan Goodenowe”